SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibito...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes
Autori principali: Tuttle, Katherine R., Brosius, Frank C., Cavender, Matthew A., Fioretto, Paola, Fowler, Kevin J., Heerspink, Hiddo J.L., Manley, Tom, McGuire, Darren K., Molitch, Mark E., Mottl, Amy K., Perreault, Leigh, Rosas, Sylvia E., Rossing, Peter, Sola, Laura, Vallon, Volker, Wanner, Christoph, Perkovic, Vlado
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Diabetes Association 2021
Soggetti:
Perspectives in Diabetes
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8162454/
https://ncbi.nlm.nih.gov/pubmed/33106255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dbi20-0040
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi